Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AirCyte-AEC
- Development stage
- Preclinical
- Lead developer
- Eyestem Research
- Modality
- Cell Therapies
01
Overview
AirCyte-AEC is a cell therapy product under development for the treatment of respiratory diseases, with a primary focus on idiopathic pulmonary fibrosis. The therapy is being developed by Eyestem Research and has reached the preclinical stage of development. While specific details about its mechanism of action are not publicly disclosed, it is categorized as a cell therapy, suggesting it likely involves the administration or transplantation of cells to repair or regenerate lung tissue affected by fibrotic disease[8][10].
- Brand names
- AirCyte-AEC
Beyond the preview
Go deeper on AirCyte-AEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AirCyte-AEC.